Objective: While the physiological responses during acute ascent to terrestrial high-altitude (HA) have the potential to alter the pharmacokinetics (PK) that define the absorption and disposition of medicinal drugs, there have been no systematic reviews and meta-analyzes performed to date.
Introduction
The complex interplay between environmental and physical stressors encountered during acute ascent to terrestrial high-altitude (HA) initiates a cascade of physiological responses that collectively serve to defend oxygen (O2) delivery to the most metabolically active organ systems (Bailey and others 2017) . However, coupling of O2 delivery to demand is imperfect and severe arterial hypoxemia can ultimately lead to medical complications ranging from mild symptoms of acute mountain sickness (AMS) to the potentially fatal syndromes of high-altitude pulmonary (HAPE)/cerebral (HACE) edema (Bailey and others 2009 ) that necessitate the use of medicinal drugs.
These physiological adjustments have the capacity to alter the pharmacokinetics (PK) that define the absorption and disposition of drugs subsequent to alterations in, amongst others, cytochrome
P (CYP)-450 activity, pH, protein binding, distribution volumes and perfusion (Figure 1 A-B).
This is clinically relevant given the millions of lowlanders who sojourn to HA for occupational, recreational, or religious purposes (Li and others 2009 ) and increasing number of mountaineers who prophylax with a cocktail of drugs in an attempt to accelerate acclimatization and improve summit success (Donegani and others 2016; Nieto Estrada and others 2017) .
However, to what extent drug PK change in response to the multiple stressors encountered at terrestrial HA (hypoxia, exercise, cold, see Figure 1 ) remains unclear, complicated in part by conflicting findings from a limited number of studies constrained by small sample sizes and limited ability to detect treatment effects with participants exposed to different drugs, altitudes and exposure times. Thus, for the first time, a systematic review and meta-analysis was conducted to summarize the results of relevant studies in an attempt to increase sample size and corresponding statistical power. The primary aim was to determine the effects of acute exposure (≤ 24 h) to terrestrial HA on drug PK with a secondary aim of determining optimal sample sizes to help guide the design of future trials.
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Methods
Database and search strategy
A systematic review of the published literature was conducted (Figure 2) 
Selection and quality assessment
Inclusion criteria: Studies were deemed eligible for meta-analysis based on the following criteria: 1] participants: healthy non-acclimatised male or female lowlanders (born and bred at sea-level)
and 2] environment: exposure to low-altitude (LA, ≤ 600 m) followed by terrestrial high-altitude (HA, ≤ 24 h to ≥ 2,500 m).
Exclusion criteria:
We excluded studies that were 1] performed on animals, 2] duplicates (originating from the same participants by the same investigators but published in different journals), 3] letters to editors, reviews, commentaries, case reports, unpublished articles and articles providing insufficient information relating to PK parameters, 4] simulated normobaric hypoxic (laboratory-based) studies given the acknowledged physiological differences compared 5 R2 to hypobaric hypoxia (Millet and others 2012) and 5] those incorporating chronic (> 24 h) exposures to avoid interpretive (PK) complications associated with erythrocytosis.
Quality: Study quality could not be formerly assessed given that none of the studies were randomised, blinded or provided sample size calculations. Final decision about inclusion or exclusion was achieved through mutual agreement.
Data extraction
The two investigators extracted data using structured data collection tables. All data entries were double-checked manually and all discrepancies resolved through discussion. The following information was extracted from selected studies: authors, publication year, experimental design, drug examined, sample size, altitude and PK parameters. The PK parameters were standardised to be in the same units and included: absorption rate constant (kA), volume of distribution as a function of bioavailability (Vd/F), mean residence time (MRT), absorption (t½A) and elimination (t½) half-lives, clearance as a function of bioavailability (CL/F), elimination rate constant (K), time to peak plasma concentration (TMAX) and erythrocyte binding (CE).
Statistical analysis
Statistical analyses were conducted using the Cochrane Review Manager software (RevMan Version 5.3.5 for Windows, Cochrane Collaboration, Oxford, UK, http://www.ccims.net/RevMan) to pool data for each of the PK parameters and associated variables. Continuous outcomes were presented as a standardized mean difference (SMD, Hedges g) along with 95% confidence intervals (CI). Effect sizes of <0.2, <0.5, <0.8 and >0.8 were considered trivial, small, moderate and large, respectively (Cohen 1992) . Heterogeneity was evaluated using the Cochran χ 2 -based Q and Higgins I 2 statistics that assess the appropriateness of pooling individual study results (Higgins and others 2003) . Random-effects models (DerSimonian and Laird 1986) were R2 applied if heterogeneity was evident (χ 2 P < 0.10/I 2 >50%) otherwise fixed-effects models (Mantel and Haenszel 1959) were employed. Publication bias was assessed using a Funnel Plot in combination with Egger et al.'s test (Egger and others 1997) . Power and sample size calculations were performed using G*Power (version 3.1.9.2). Significance was established at P < 0.05 for all two-tailed tests and data presented as mean ± SD unless otherwise stated.
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Results
Study identification and characteristics
Applying the search terms, a total of 20,840 publications were identified, out of which ten were considered relevant after initial screening by title and abstract ( Figure 2 ). After applying the inclusion and exclusion criteria, six full-text articles employing separate drugs were selected for meta-analysis (Table 1 ). The general properties of the six drugs are summarized in Table 2 . These articles constituted non-randomized single-arm studies comprising a total of 75 healthy males of either Chinese or Chilean descent. Participants were 21 ± 3 years old and exposed to both LA (267 ± 301 m) and HA (4,025 ± 380 m) for 14.2 ± 1.7 h. There was no consistent evidence of systematic publication bias (P > 0.05).
Outcomes
The drugs appeared to be well tolerated since there were no serious adverse events reported. Figure   3 provides a summary of the mean changes (SMD) observed in each of the PK parameters documented at HA based on the individual studies (Supplementary Figures, S1a-S1j). We observed significant increases for t½A (SMD: 0.40, P = 0.04) and t½ (SMD: 0.89, P = 0.003) while the hybrid parameter CL/F showed a corresponding reduction (SMD: -0.56, P = 0.05). These were considered of potential physiological significance given the SMD "cut-off" of ≥ 0.50 standardized units as illustrated (Figure 3 ). In contrast, no changes (P > 0.05) were observed in the remaining parameters, notably kA, TMAX, Vd/F or K (latter SMD: -0.53). Similarly MRT while not significant, showed a marked tendency to be increased (SMD: 0.56, P = 0.09). Finally and as expected, significant increases in Hct (SMD: 1.02, P = 0.01) and CE (SMD: 0.52, P = 0.004) were observed.
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Statistical power and sample size
Post-hoc analyses revealed that studies were generally underpowered with no singular pharmacokinetic parameter achieving the (minimal) requisite power of 0.8 (Figure 4 ). Prospective calculations indicated that sample sizes needed to be in the order of ~2 to over 1,500 fold larger in order to be adequately powered to detect a treatment effect.
R2
Discussion
This systematic review and meta-analysis has revealed important changes in PK parameters that define the absorption and disposition of an albeit limited selection of medicinal drugs displaying diverse physico-chemical and PK properties that may be indicative of a broader impact of the HA environment upon the body's handling of pharmaceuticals. First, by pooling relevant studies and improving statistical power, our analysis extends original works described in a published review (Hui and others 2016) highlighting impairments in both the oral absorption and corresponding clearance of drugs that from a clinical perspective, encourage the need for closer patient monitoring and dose adjustments in order to maintain therapeutic efficacy and avoid incidental toxicity. Second, prospective calculations have helped inform the design of future trials highlighting the need for considerably larger sample sizes to more rigorously address PK changes and ultimately define safer, more effective pharmacological interventions at HA.
The overall outcomes of our analysis highlighted a significant prolongation in t 1 /2A at HA. This change in rate is not necessarily underpinned by any change in the extent of absorption [bioavailability (F)], a parameter not reported in any of the primary studies forming this metaanalysis. Our analysis would suggest that the data for sulfamethoxazole, meperidine and lithium made the greatest contribution to the overall absorption outcomes of our study. These drugs possess different biopharmaceutical characteristics in respect to the Biopharmaceutics Classification System (BCS) for orally administered drugs (Kasim and others 2004) .
Sulfamethoxazole is a Class IV drug (low permeability and low solubility) whereas meperidine and lithium (WHO 2005) are Class I drugs (high permeability and high solubility). The other drugs in the analysis being: acetazolamide (Class IV), furosemide (Class IV) and prednisolone (Class I).
However, there is little that can be concluded from such biopharmaceutical characteristics in terms of a unifying mechanism to support a slower absorption rate at HA and the BCS system itself does not provide a definitive measure of in-vivo absorption outcomes.
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Acute exposure to HA is often associated with gastrointestinal complaints attributed to delayed gastric emptying, although more severe hypoxemia associated with higher elevations (>5000 m)
is typically required before nutrient malabsorption becomes apparent ( We observed a consistent increase in CE that has traditionally been attributed to an increase in Hct and/or total protein including albumin assuming CE includes all sources of binding in blood (Hui and others 2016 ). In the current study, we specifically chose to focus our attention on acute HA exposure (< 24 h) and thus confident that the increase in CE was unrelated to any increase in erythrocyte mass given the 2-3 day time-lag between erythropoiesis and de novo appearance of reticulocytes in the circulation. Thus, the increased Hct observed likely reflects an apparent hemoconcentration subsequent to hyperventilation/diuresis-induced plasma volume contraction, notwithstanding potential increases in capillary hydrostatic and interstitial osmotic pressures that collectively drive fluid from the intravascular to the extravascular space (Fall and others 2011) .
The analysis revealed a consistent and significant trend for the CL/F parameter to be reduced at HA. The decrease in CL/F could reflect decreases in CL and/or increases in F. However increases 11 R2 in F would not be consistent with a trend for a reduced rate of absorption and moreover the Vd/F parameter remained essentially unchanged indicating neither Vd or F to have changed significantly, or both parameters to have changed in a simultaneous and directly proportional manner, i.e. if F were to have increased then Vd would also need to have increased in direct proportion. In this context while acute HA exposure can be associated with fluid extravasation any such conductive fluid transfer would not in its own right change the effective estimate for Vd, when this estimate is based upon total drug plasma concentrations, which is indeed the case in the primary studies underpinning the analysis of this systematic review. As such we interpret the reduced CL/F to reflect a decrease in CL per se, entirely consistent with the prolonged t½ and indeed the trend for MRT to be prolonged in the studies, although it is important to note that the method of calculation of the MRT parameter was not explicitly defined in most of the primary works. The apparent discrepancy between t½ and K (the latter not significant), although trending towards an (expected) inverse relationship, is a likely consequence of the marked heterogeneity of the SMDs associated with each of the selected studies.
Previous observed or presumed decreases in drug CL at HA have more often than not been interpreted in the context of altered capacity for enzymatic metabolism, particularly diminished monooxygenase activity of CYP-450 for which O2 is a substrate (Fradette and Du Souich 2004 ).
However, a drug's CL (i.e. one based on measurement of total protein-bound and free drug levels) may also be impacted by changes in drug plasma protein binding. This is particularly the case for those drugs displaying medium to low extraction efficiencies across an organ ( Figure 1A ) warrant investigation (Bailey 2017 ).
However, these findings contrast with those reported during more controlled laboratory-based exposures to normobaric hypoxia. In one of the most rigorous trials conducted to date, 2 h passive exposure to a simulated altitude of 4,500 m failed to alter hepatic blood flow and corresponding metabolism of theophylline (low hepatic extraction ratio metabolized mainly by CYP1A2) and verapamil (high hepatic extraction ratio metabolized mainly by CYP3A4), arguing against the need for dose adjustment (Streit and others 2005) . Differences between normobaric versus hypobaric hypoxia (Millet and others 2012) notwithstanding the contributory impact of additional stimuli such as exercise, cold and psychological stress exclusive to terrestrial ascent (Bailey 2017; Peng and Cheung 2009; Peng and Cheung 2011 ) may contribute at least in part to these conflicting findings and clearly highlight the need for further research.
Limitations
It is important to recognize the limitations associated with the current meta-analysis. Our findings are restricted to participants of either Chilean or Chinese descent and thus the interpretive implications for other ethnic groups remains unclear, especially given established differences in the catalytic activities of CYP-450 isoforms (Yang and others 2012) . Furthermore and subject to inclusion/exclusion criteria, our analysis was confined to a limited selection of compounds that exhibit diverse clearance pathways and thus it is unlikely that changes in active tubular ion exchange, oxidative metabolism, phase II pathways such as N-acetylation, sulfation, and glucuronidation or active tubular efflux can collectively be ascribed to a single "common mechanism" induced by HA. The situation is clearly more complex, further complicated by exposure to multiple stressors whose independent and combined impact on drug PK remain largely unknown. Equally, it may be considered pharmacologically unfounded to pool study data from such physiochemically diverse compounds, the fundamental basis of a meta-analysis, though we have adhered to stringent guidelines (Knobloch and others 2011; Walker and others 2008) including a description and evaluation of heterogeneity, to optimize the validity of our findings.
Conclusion
This analysis reveals impairments in both the oral absorption and corresponding clearance of an albeit limited sample of drugs that exhibit diverse clearance pathways that may potentially require modifications in dosage regimens to maintain efficacy or prevent toxicity especially for those with a narrow therapeutic index. Given that studies have traditionally been underpowered, characterized by a high degree of variability and relatively small effect sizes, larger scale randomized controlled trials in humans are encouraged to better define safer and more effective pharmacological interventions at HA including the experimental (laboratory-based) isolation of the independent and combined influences of the composite PK-modulating stressors (hypoxia, exercise, cold). Given
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